Abstract
Hepatitis B virus (HBV) reactivation during anticancer chemotherapy or immunosuppressive therapy in chronic carriers can lead to fatal liver failure. We report a rare case of severe HBV reactivation during postoperative radiotherapy with concomitant and adjuvant temozolomide (TMZ) for malignant glioma. A 49-year-old Japanese woman with a history of HBV carrier status with positive results for hepatitis B surface antigen presented with persistent headache due to a tumor in the left frontal lobe. The tumor was partially resected and anaplastic astrocytoma was diagnosed. Postoperative liver function was normal and radiotherapy plus concomitant and adjuvant TMZ was started. Impaired liver function became apparent just before administration of adjuvant TMZ, and acute liver failure developed. Antiviral therapy including entecavir, a nucleoside analog, led to a successful outcome and the patient survived. This case underlines the possibility of HBV reactivation due to TMZ and suggests the utility of HBV screening and antiviral prophylaxis before administration of TMZ to patients with malignant glioma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Galbraith RM, Eddleston AL, William R et al (1975) Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug chemotherapy. Lancet 2:528–530
Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699–712
Law JK, Ho JK, Hoskins PJ et al (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085–1089
Yeo W, Chan PK, Zhong S et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307
Yeo W, Zee B, Zhong S et al (2004) Comprehensive analysis undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311
Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temosolomide. J Clin Oncol 20:1375–1382
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996
Chheda MG, Drappatz J, Greenberger NJ et al (2007) Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 68:955–956
Grewal J, Dellinger CA, Yung WKA (2007) Fatal reactivation of hepatitis B with temozolomide. N Eng J Med 356:1591–1592
Leaw SJ, Yen CJ, Huang WT et al (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270–275
Markovic S, Drozina G, Vovk M et al (1999) Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46:2925–2930
Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24:1003–1016
Lok ASF, Liang RHS, Chiu EKW et al (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188
Tur-Kaspa R, Burk RD, Shaul Y et al (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83:1627–1631
Pei SN, Chen CH, Lee CM et al (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HbsAg-negative patients. Ann Hematol 89:255–262
Lok ASF, NcMahon BJ (2007) Chronic hepatitis B. Heapatology 45:507–539
Lok ASF, NcMahon BJ (2009) Chronic hepatitis B: update 2009. Heapatology 50:661–662
Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37:705–712
Tsubouchi H, Kumada H, Kiyosawa K et al (2009) Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection–Joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis (in Japanese). Kanzo 50:38–42
Idilman R (2006) Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut 55:1208–1209
World Health Organization (2008) Hepatitis B (Fact sheet No. 204). Geneva, WHO. http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed August 2008
Tanaka J, Koyama T, Mizui M et al (2011) Total number of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. doi:10.1159/000324525
Fujisaki S, Yokomaku Y, Shiino T et al (2011) Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 49:1017–1024
Acknowledgments
The authors did not receive any funding that supported this study.
Conflict of interest
No author has any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Fujimoto, Y., Hashimoto, N., Kinoshita, M. et al. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol 17, 290–293 (2012). https://doi.org/10.1007/s10147-011-0294-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-011-0294-3